Previous 10 | Next 10 |
Viatris Inc. (VTRS) Q4 2022 Earnings Conference Call February 27, 2023 08:30 AM ET Company Participants Robert Coury - Executive Chairman Scott Smith - Incoming Chief Executive Officer Michael Goettler - Chief Executive Officer Rajiv Malik - President Sanjeev N...
The following slide deck was published by Viatris Inc. in conjunction with their 2022 Q4 earnings call. For further details see: Viatris Inc. 2022 Q4 - Results - Earnings Call Presentation
The futures pointed to a higher open at the start of Monday's trading, as Wall Street looks to bounce back from the decline that marked the end of last week. Here are some stocks to watch on Monday: Union Pacific ( NYSE: UNP ) surged almost 10% in premarket trading after the company...
SAN DIEGO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that its President, Scott Smith, will...
Viatris ( NASDAQ: VTRS ) has appointed Scott A. Smith as new Chief Executive Officer, effective April 1, 2023. Michael Goettler will work with Smith for a seamless transition and will then depart as CEO and as a member of the board. Smith has been a member ...
Viatris Announces Appointment of Scott A. Smith as CEO Effective April 1, 2023 PR Newswire Smith, a seasoned senior healthcare executive, will lead the company's previously announced Phase 2 strategy and execution Board of Directors thanks Michael Goettler , who wi...
Viatris ( NASDAQ: VTRS ) posted $1.0B GAAP net income for Q4 2022 on Monday compared to a $263.8M net loss in the prior year, thanks to a one-off gain of ~$1.8B related to its biosimilar divestiture. In November 2022, India's Biocon Biologics acquired the company's biosimilar...
Viatris press release ( NASDAQ: VTRS ): Q4 GAAP EPS of $0.83 beats by $0.68 . Revenue of $3.87B (-10.6% Y/Y) misses by $120M . 2023 Guidance Midpoint Reflects Revenue Growth Over 2022, Excluding Full-Year Impact of Biosimilars. Reaffirms 2024 Phase 2 Outlook fr...
Viatris Reports Strong Fourth Quarter and Full Year 2022 Financial Results and Provides 2023 Financial Guidance PR Newswire PITTSBURGH , Feb. 27, 2023 /PRNewswire/ -- Company Meets its 2022 Adjusted Guidance After Incorporating the Fourth Quar...
Viatris ( NASDAQ: VTRS ) is scheduled to announce Q4 earnings results on Monday, February 27th, before market open. The consensus EPS Estimate is $0.72 (vs. -$0.22 last year) and the consensus Revenue Estimate is $3.99B (-7.9% Y/Y). Over the last 1 year, VTRS has beaten EPS ...
News, Short Squeeze, Breakout and More Instantly...
2024-07-26 12:25:00 ET The late comedian Rodney Dangerfield was famous for his catchphrase, "I don't get no respect." Does Dangerfield's line apply to some stocks today? Absolutely. Three Motley Fool contributors think they've found surprisingly underrated pharmaceutical stocks to b...
NORTHAMPTON, MA / ACCESSWIRE / July 23, 2024 / No country can make every medicine people need, and no medicine is made in every country. If a country or region relies on supply only from within their region and they experience a crisis, there is a risk people won't get the medicines they need, w...
NORTHAMPTON, MA / ACCESSWIRE / July 18, 2024 / Viatris is a global healthcare company focused on bringing high-quality medicines to patients through a hybrid approach that bridges the traditional divide between generics and brands, combining the best of both, to more holistically address healthc...